Wednesday, April 18, 2007

Appetite Suppressants

Appetite suppressants, sweeteners and more…
Fabuless is a new natural ingredient developed for use in dairy products. It is produced exclusively for Dutch ingredients group DSM by Swedish-based Lipid Technologies Provider and used in dairy applications.
It is an oil-in-water emulsion that consists of a minimal amount of palm and oat oil. The specific oat fraction digests very slowly, allowing the ingredient to penetrate deeply into the intestinal system. The body will identify a relatively high level of undigested fat at a relatively late stage of the digestive process. In this way the hunger signals it would normally start sending are suppressed.
DSM says that independent clinical studies show that respondents using Fabuless not only eat less, but still feel pleasantly satisfied. The company can help food producers to develop products that fit their brand and will provide hands-on experience in all processing and technical aspects. Recently, Portuguese manufacturer Adagio introduced an appetite-reducing fermented milk drink, Adagio Versus, based on Fabuless.
It adds that the well-established safety of the main raw materials makes it easier to introduce into the food category than many other nutraceuticals designed to help control weight, such as botanicals or new ingredients not traditionally used in foods. These must be submitted to European authorities with a safety dossier before being permitted on the market.
Cargill offers Xtend Sucromalt from its sweetener portfolio, a slow-release carbohydrate that promises a sustained energy release and a lower glycaemic response, meaning longer-lasting satiety. The company also offers Xtend Isomaltulose, a slowly digestible sweetener.
Xtend Sucromalt is derived from sucrose and maltose, provides the full energy of sucrose, and has a clean, sweet taste. Because it is a syrup, it allows food and beverage manufacturers to apply the benefits of a sugar alternative with slow energy release and low glycaemic response to an even wider range of applications. It can also replace multiple sweeteners and bulking agents in many formulations. This allows food manufacturers to simplify ingredient labels and potentially reduce the amount of simple sugars in the formulation.
While not yet included in the US Code of Federal Regulations to allow a dental health claim, Xtend Isomaltulose is tooth friendly, which means it cannot be fermented by bacteria in the mouth and therefore supports oral health.
Anne Mollerus, global product line manager, says the company is seeking EU approval for Xtend Sucromalt while Xtend Isomaltulose already has novel foods approval in Europe. Both sweeteners have GRAS (Generally Recognised As Safe) status in the United States and together they offer the benefits of slow energy release, a blunted glycaemic response and a sweet taste for a very wide range of applications.
Xtend Isomaltulose is obtained from sucrose by enzymatic conversion. It provides the full energy of both glucose and fructose, but is released over a longer period of time. It has a clean, sweet taste and, because it is a syrup, it enables food and beverage manufacturers to apply the benefits of a sugar alternative with slow energy release and low glycaemic response to an even wider range of applications. The slow energy release supports a balanced energy supply to muscle and brain, making the product perfect for the formulation of sports drinks, energy drinks and tablets, cereal bars and meal replacements.
Dr. Fred Brouns, Cargill's manager of Nutritional Sciences Europe, says, "Our research gives a good initial indication that Xtend Isomaltulose triggers the body's satiety regulating mechanisms - which potentially helps make a person feel more full and reduces hunger pangs. In addition, Isomaltulose, through its low blood glucose and insulin response helps the body to burn more fat as a source of energy, compared to when consuming normal sugar. Both of these are promising for developing new products in the context of increased prevalence of obesity, especially in children."

No comments: